Abstract:In many respects, the most remarkable chemical substances within the genome of eukaryotic cells are remarkable proteins which are the critical structural and functional units of living cells. The specifications for everything that goes in the cell are natural digital-to-digital decoding process in an archive sequence by deoxyribonucleic acid (DNA) and an articulate construction by ribonucleic acid (RNA). The products of DNA transcription are long polymers of ribonucleotides rather than deoxyribonucleotides and are termed ribonucleic acids. Certain deoxyribonucleotide sequences, or genes, give rise to transfer RNA (tRNA) and other ribosomal RNA (rRNA) when transcribed. The ribonucleotide sequences fold extensively and rRNA is associated with specific proteins to yield the essential cell components, ribosomes. Transcription of other special sequences yields messenger RNAs (mRNAs) that contain ribonucleotide sequences that will be ultimately translated into new types of amino acid sequences of functional cellular protein molecules. This switch to a different variety of cellular molecular sequences is complex, but each sequence of the three ribonucleotides specifies the insertion of one particular amino acid into the polypeptide chain under production. Whilst mRNA is considered the vehicle by which genetic information is transmitted from the genome and allocated in the appropriate cytoplasmic sites for translation into protein via cap-dependent mechanism, the actual translation depends also on the presence of other so-called household and luxury protein molecules. Recent evidence suggests RNA species are required at initiation, because treatment of cells with antibiotics or drugs that inhibit RNA synthesis cause a decrease in protein synthesis. The rRNA is necessary as a structural constituent of the ribosomes upon which translation takes place, whereas tRNA is necessary as an adaptor in amino acid activation and elongation protein chains to ribosomes. In this article, we review malignant tumor, with stem like properties, and recent technical advances into the phenomenon of micro-particles and micro-vesicles containing cell-free nucleic acids that circulate plasma. New areas of research have been opened into screening tumor telomerase progression, prognosis of aptamers targeting cell surface, monitoring the efficacy of anticancer therapies, oncogenic transformation of host cell, and RNA polymerases role in the cell cycle progression and differentiation.

Ribosome RNA Modification in Cancer: Biological Functions and Therapeutic Targets.

Decoding the ribosome's hidden language: rRNA modifications as key players in cancer dynamics and targeted therapies

The Regulation of Protein Translation and Its Implications for Cancer

Role of Main RNA Modifications in Cancer: N6-methyladenosine, 5-Methylcytosine, and Pseudouridine

Translational Regulation by eIFs and RNA Modifications in Cancer

Tuning the ribosome: The influence of rRNA modification on eukaryotic ribosome biogenesis and function

RNA modifications in cancer

The diverse landscape of RNA modifications in cancer development and progression

Ribonucleic acid (RNA) biosynthesis in human cancer

Trna Modifications: Insights into Their Role in Human Cancers.

Biological roles of RNA m5C modification and its implications in Cancer immunotherapy

The Roles of M6a RNA Modifiers in Human Cancer

Novel Insight into the Regulatory Roles of Diverse RNA Modifications: Re-defining the Bridge Between Transcription and Translation

RNA Modifications in Hematologic Malignancies.

RNA modification: mechanisms and therapeutic targets

Eukaryotic translation initiation factors and cancer.

Regulations of m6A and other RNA modifications and their roles in cancer

The roles of m<SUP>6</SUP>A RNA modifiers in human cancer

Trna Modifications and Modifying Enzymes in Disease, the Potential Therapeutic Targets

Visualization of chemical modifications in the human 80S ribosome structure

Dysregulation of tRNA methylation in cancer: Mechanisms and targeting therapeutic strategies